Exploring Data and Literature Currently Available on the COVID-19 Vaccines

Gogia, Pooja; Ashraf, Hamza; Bhasin, S.; Frenia, Douglas

doi:10.55729/2000-9666.1001

Cited by 1 publication

(3 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…An activating BRAF V600E mutation is seen in 38–64% of LCH and Erdheim–Chester disease (ECD) cases and more frequently in mixed LCH/ECD ( 16 ). In RDD, however, no single dominant mutation has been found, though Kirsten rat sarcoma virus (KRAS) and MAP2K1 mutations have been described in 33% of cases of Rosai–Dorfman disease ( 3 , 19 ). A published case report of a patient with RDD and a KRAS mutation responded well to targeted therapy with cobimetinib ( 20 ).…”

Section: Discussionmentioning

confidence: 99%

“…Widespread vaccination against SARS-CoV-2 has been considered the most promising approach to curbing the pandemic. mRNA vaccines have been widely used and show a high degree of immunogenicity, a high safety profile, and high efficacy in inducing immune responses against SARS-CoV-2 ( 3 ). Multiple case reports of patients with vaccination-induced lymphadenitis after COVID-19 vaccination have been published, as described in a systematic review ( 31 ).…”

Section: Discussionmentioning

confidence: 99%

“…Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a virus that has caused an outbreak of the illness Coronavirus disease 2019 (COVID- 19), which has been declared a public health emergency by the World Health Organization (WHO), an agency of the United Nations responsible for international public health (3). In individuals infected with COVID-19, there is a dysregulation of the adaptive immune response that leads to a cytokine storm and widespread multi-organ involvement (4).…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Case report: A rare case of Rosai–Dorfman–Destombes disease after the COVID-19 infection

et al. 2022

Self Cite

View full text Add to dashboard Cite

Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is known to cause immune dysregulation and, therefore, has varied and often rare presentations. Rosai–Dorfman–Destombes disease (RDD) is an unusual non-Langerhans cell (non-LC) histiocytosis presenting with massive lymphadenopathy and various systemic symptoms. A 55-year-old Asian-American woman with no significant medical history or recent use of new drugs initially presented with cervical lymphadenopathy and urticarial rash 1 week after receiving the COVID-19 messenger RNA (mRNA) vaccine (Moderna, mRNA-1273) against SARS-CoV-2. The biopsy of the skin rash was consistent with a drug reaction. Approximately 2 months later, she developed mild flu-like symptoms and was diagnosed with a COVID-19 infection. Her symptoms were mild and self-resolving. Approximately 3 months later, she developed a generalized patchy erythematous rash on the face and the body that gradually worsened; diffuse lymphadenopathy involving the bilateral cervical, axillary, and inguinal areas; and constitutional symptoms. Laboratory results were consistent with lymphopenia, anemia, and an elevated sedimentation rate. Supraclavicular lymph node biopsy showed Rosai–Dorfman disease with a marked polyclonal plasmacytosis. She was started on a tapering dose of corticosteroids and showed clinical improvements over the next few weeks. Herein, we present a rare case of a histiocytic disorder that developed after contracting the SARS-COV2 infection in the event of receiving a recent mRNA COVID vaccination.

show abstract